NCODA Logo

The purpose of this PQI is to provide background on bispecific T-cell engagement and discuss the proper patient selection and prevention of adverse events related to the administration of mosunetuzumab-axgb in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.